- AIDS treatment, centered around antiretroviral therapy (ART), is an essential component of global healthcare aimed at managing HIV infection, preventing disease progression, and reducing transmission through sustained viral suppression across both developed and developing healthcare settings
- The rising demand for AIDS treatment is primarily driven by the increasing global prevalence of HIV, expanding public health initiatives, and improved access to affordable and effective ART regimens supported by international health organizations and government programs
- North America dominated the acquired immunodeficiency syndrome (AIDS) treatment market with the largest revenue share of 42.3% in 2024, characterized by advanced healthcare systems, early adoption of innovative treatment options, high awareness levels, and strong pharmaceutical R&D pipelines, particularly in the U.S., which continues to lead in ART development and deployment
- Asia-Pacific is expected to be the fastest growing region in the acquired immunodeficiency syndrome (AIDS) treatment market during the forecast period due to increasing HIV incidence, rising healthcare expenditures, and expanded access to ART programs supported by regional governments and international collaborations
- Nucleoside/nucleotide reverse transcriptase inhibitors segment dominated the acquired immunodeficiency syndrome (AIDS) treatment market with a market share of 40.1% in 2024, driven by its proven efficacy, inclusion in first-line treatment guidelines, and widespread global usage
